PEMBROLIZUMAB (KEYTRUDA) prior authorization at Point32Health
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Point32Health reviews PEMBROLIZUMAB (KEYTRUDA) prior authorizations against its medical policy for Programmed Death Receptor-1 Blocking Antibody [EPC]. The FDA-approved indication (2014) is SOLUTION. Point32Health-specific context: Formed by 2021 merger of Tufts Health Plan and Harvard Pilgrim Health Care; ~2M members across New England. Brands operate separately (Harvard Pilgrim, Tufts Health Plan). MA DOI primary regulator; MA OPP external review applies in Massachusetts.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Programmed Death Receptor-1 Blocking Antibody [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Point32Health's medical policy URL referenced in the cover letter
Point32Health's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Harvard Pilgrim vs Tufts Health Plan operational differences (pre-merger legacy)
- MA mandated benefit disputes
- Specialty drug PA
- Behavioral health prior auth
If the PA is denied
Point32Health gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.point32health.org/providers) with the same packet plus a peer-reviewed citation supporting PEMBROLIZUMAB (KEYTRUDA)for the patient's indication.
Contact Point32Health
- Provider portal: https://www.point32health.org/providers
Frequently asked questions
What documentation does Point32Health need for PEMBROLIZUMAB (KEYTRUDA) prior auth?
Point32Health's typical PA packet for PEMBROLIZUMAB (KEYTRUDA): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Programmed Death Receptor-1 Blocking Antibody [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at Point32Health?
Standard PEMBROLIZUMAB (KEYTRUDA) PA decisions at Point32Health: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Point32Health most often reject PEMBROLIZUMAB (KEYTRUDA) for?
Across Point32Health's book the common rejection patterns include: Harvard Pilgrim vs Tufts Health Plan operational differences (pre-merger legacy); MA mandated benefit disputes; Specialty drug PA. For PEMBROLIZUMAB (KEYTRUDA) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Point32Health on PEMBROLIZUMAB (KEYTRUDA)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the PEMBROLIZUMAB (KEYTRUDA) PA packet
Open ApprovalHelp — generate a PEMBROLIZUMAB (KEYTRUDA) prior-auth packet tailored to Point32Health's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com